Behavioral Health

Benzodiazepine use disorder and withdrawal

Clinical Overview and When to Suspect Benzodiazepine Use Disorder

— Patient requests early refills, reports "lost" prescriptions, or escalates dose without authorization

— Multiple prescribers/pharmacies on the state PDMP (always check before refill in Step 3 vignettes)

— Co-use with opioids, alcohol, or z-drugs (zolpidem)

— Sedation, falls, memory gaps, or motor vehicle crashes in an older patient on chronic alprazolam/lorazepam

— ED visits for "panic attacks" that resolve only with IV lorazepam

— Short half-life, high-potency agents (alprazolam, lorazepam, triazolam) carry highest abuse and withdrawal liability

— Rapid-onset oral absorption (alprazolam IR) reinforces use; clonazepam and diazepam misuse is also common but withdrawal is more protracted

Board pearl: A Step 3 stem describing a 34-year-old on alprazolam 2 mg QID for "anxiety" who now needs 3 mg doses and gets them from two prescribers = BUD. The first move is not to abruptly stop the BZD — it is to verify the PDMP, assess withdrawal risk, and plan a structured taper, ideally after converting to a long-acting agent like diazepam or clonazepam.

Benzodiazepine use disorder (BUD) is a DSM-5 substance use disorder defined by ≥2 of 11 criteria over 12 months: tolerance, withdrawal, escalating dose, craving, failed cutdown, role impairment, hazardous use, continued use despite harm, time spent obtaining, social sacrifice, and use in physical danger.

Prevalence anchors: ~12–15% of US adults filled a benzodiazepine (BZD) prescription in the past year; ~2% meet criteria for misuse. BZDs are involved in ~30% of opioid overdose deaths via respiratory synergy.

When to suspect in clinic:

High-risk populations: patients with prior substance use disorder, untreated PTSD, chronic pain on opioids, and elderly on long-standing "as needed" anxiolytics from the 1990s–2000s.

Pharmacologic risk drivers:

Presentation Patterns and Key History

— Active misuse / use disorder: craving, dose escalation, doctor shopping, snorting or IV use of crushed alprazolam, co-ingestion with opioids

— Acute withdrawal: in a patient who stopped abruptly (ran out, hospitalized, jailed, or "tapered too fast")

— Protracted withdrawal syndrome: weeks-to-months of anxiety, insomnia, paresthesias, perceptual disturbance after taper completion

— Short-acting (alprazolam, lorazepam, oxazepam): symptoms begin 6–24 h after last dose, peak 1–4 days

— Long-acting (diazepam, clonazepam, chlordiazepoxide): onset 24–72 h, peak 5–8 days, can persist 2–4 weeks

— Autonomic: tachycardia, hypertension, diaphoresis, tremor, mydriasis

— Neuro: anxiety, insomnia, perceptual hyperacusis, photophobia, paresthesias

— Severe: seizures (generalized tonic-clonic), delirium, psychosis, hyperthermia

— Exact agent, dose, frequency, last dose, duration of use (>4 weeks = physiologic dependence likely)

— Source: single prescriber vs multiple vs illicit ("Xanax bars" pressed pills often contain fentanyl)

— Prior withdrawal episodes, seizures, DTs

— Co-use: alcohol (CIWA risk), opioids (overdose risk), stimulants

— Function: driving, work, parenting, falls

— Use to "come down" from stimulants

— Combining with opioids for euphoria

— Crushing/snorting; "pharm parties"

— Buying from non-medical sources

Step 3 management: Always quantify diazepam equivalents — alprazolam 1 mg ≈ diazepam 10 mg, lorazepam 1 mg ≈ diazepam 5 mg, clonazepam 0.5 mg ≈ diazepam 10 mg. This guides both taper and acute withdrawal dosing decisions in your CCS case.

Three overlapping clinical presentations dominate Step 3 vignettes:

Withdrawal timeline by agent:

Cardinal withdrawal symptoms — mirror alcohol withdrawal:

Key history questions (CCS-style orders include "Ask about..."):

Red flags suggesting use disorder rather than therapeutic use:

Physical Exam Findings and Hemodynamic Assessment

— Sedation, slurred speech, ataxia, nystagmus (horizontal gaze-evoked)

— Normal or slightly constricted pupils (vs opioid miosis); pupils are not a reliable discriminator

— Hyporeflexia, hypotonia

— Respiratory depression uncommon with oral BZD alone in benzodiazepine-tolerant patient — but lethal when combined with opioids, alcohol, or in IV/snorted use

— Hypotension and bradycardia possible with massive overdose or IV midazolam

— HR >100, SBP >140, RR elevated, temp may be low-grade febrile

— Postural/intention tremor of outstretched hands (fine, high-frequency)

— Diaphoresis, piloerection, hyperreflexia, clonus

— Mydriasis with sluggish reaction

— Tongue fasciculations, jaw tremor

— Temperature >38.5°C

— Disorientation, visual/tactile hallucinations (formication)

— Witnessed seizure

— SBP >180 or HR >120 despite initial dosing

— Vitals q1h initially → q4h once stable

— Continuous telemetry if severe or polysubstance

— Orthostatic vitals before discharge from observation

— CIWA-Ar or CIWA-B scale to trend severity — same instrument used for alcohol, validated in BZD withdrawal

— Asterixis → hepatic encephalopathy (often coexists in alcohol+BZD users)

— Focal neuro deficit → CVA, subdural (fall risk)

— Track marks → IV use, endocarditis risk

Board pearl: A patient with BZD withdrawal who develops fever, rigidity, and altered mentation is not "just severe withdrawal" — rule out NMS, serotonin syndrome, meningitis, and anticholinergic toxicity before attributing to BZD alone. CCS expects parallel workup, not anchoring.

Intoxication exam (parallels alcohol intoxication without the odor):

Withdrawal exam — autonomic hyperactivity:

Severe withdrawal signs requiring escalation:

Hemodynamic assessment framework (CCS sequence):

Exam findings suggesting alternative or comorbid diagnosis:

Diagnostic Workup — Initial Labs, Imaging, ECG, Biomarkers

— Urine drug screen (UDS) with BZD-specific GC/MS confirmation

— Ethanol level (BAL)

— CBC, CMP (LFTs, renal function affect BZD clearance)

— Magnesium, phosphate (often low in chronic alcohol co-use)

— TSH (mimics anxiety)

— Pregnancy test (β-hCG) in reproductive-age women — alters management

— ECG: QTc baseline, especially if planning antipsychotic adjunct

— Standard immunoassay detects oxazepam metabolite → misses alprazolam, lorazepam, clonazepam, midazolam (negative UDS does NOT exclude use)

— Order GC/MS or LC-MS confirmation when clinical suspicion is high but immunoassay negative

— False positives: sertraline, oxaprozin

— Therapeutic single dose: 1–3 days

— Chronic use (diazepam, clonazepam): up to 30 days in urine due to long-half-life metabolites

— Non-contrast head CT if: fall with LOC, focal deficit, anticoagulated, age >65, witnessed seizure

— CXR if aspiration suspected (post-overdose)

— CIWA-B (benzodiazepine-specific): graded 0–20 mild, 20–35 moderate, >35 severe

— PDMP query — counts as a "diagnostic" order in CCS

— PHQ-9, GAD-7 to clarify underlying psychiatric comorbidity driving use

Key distinction: Flumazenil is diagnostic and therapeutic in pure pediatric or iatrogenic BZD overdose only. In chronic BZD users or polysubstance overdose (especially with TCAs or unknown ingestion), flumazenil can precipitate seizures and status epilepticus by abruptly unmasking withdrawal. On Step 3, flumazenil is almost always the wrong answer in adult overdose — supportive care with airway protection is correct.

Core initial workup for suspected BZD use disorder or withdrawal:

UDS pitfalls — critical Step 3 trap:

Detection windows:

Imaging — selective, not routine:

Biomarker/risk tools:

Diagnostic Workup — Advanced or Confirmatory Studies

— LC-MS/MS comprehensive drug panel — detects designer BZDs (etizolam, flualprazolam, clonazolam, bromazolam) increasingly found in counterfeit "Xanax" pills purchased online

— Fentanyl and xylazine testing — counterfeit alprazolam tablets frequently contaminated; xylazine causes prolonged sedation unresponsive to naloxone

— Acetaminophen and salicylate levels in any intentional overdose

— Suspected non-convulsive status epilepticus in altered patient post-withdrawal seizure

— Persistent confusion >24 h after metabolic correction

— BZD withdrawal can produce diffuse slowing; chronic use shows increased beta activity

— Persistent cognitive deficit after detox (rule out Wernicke, anoxic injury, chronic subdurals from falls)

— Atypical features (focal seizure, asymmetric exam)

— Structured diagnostic interview to clarify primary anxiety disorder, PTSD, panic disorder, or bipolar II that may have driven initial prescribing

— Validated tools: CIDI, MINI, or in clinic the SCID-5

— Screen comorbid SUDs: AUDIT-C for alcohol, DAST-10 for other drugs

— Cirrhosis or CKD shifts choice toward oxazepam, lorazepam, or temazepam ("LOT" — non-CYP, glucuronidated, no active metabolites)

— Check albumin (protein binding affects free drug)

CCS pearl: In your CCS case, after admitting a withdrawing patient, order CIWA-B q2h, magnesium/phosphate replacement, thiamine 100 mg IV before glucose (if any alcohol co-use), and a psychiatry consult within the first 24 hours — early multidisciplinary engagement improves taper completion and is graded favorably.

When initial workup is non-diagnostic or atypical, escalate to:

EEG indications:

Neuroimaging — MRI brain if:

Polysomnography in patients with chronic insomnia driving BZD use — frequently uncovers obstructive sleep apnea, which BZDs worsen and which is a non-pharmacologic therapeutic target.

Confirmatory psychiatric assessment:

Hepatic and renal staging before long taper:

Risk Stratification and First-Line Management Logic

— Mild (CIWA-B <20), no seizure history, reliable, supports available → outpatient gradual taper

— Moderate (20–35) OR seizure history OR polysubstance OR pregnancy OR unstable housing → admit for monitored taper

— Severe (>35), active seizure, delirium, hyperthermia, hemodynamic instability → ICU

— Duration of use >6 months

— Daily diazepam-equivalent dose >40 mg

— Short-acting, high-potency agent (alprazolam)

— Abrupt cessation (vs taper)

— Prior withdrawal seizure or DT

— Concurrent alcohol or barbiturate dependence

— Age >65, hepatic dysfunction

— Never stop BZDs abruptly in physiologically dependent patients (>4 weeks daily use) — withdrawal seizures and death documented

— Convert short-acting → long-acting agent (diazepam or clonazepam) using equivalence table, then taper

— Taper rate: 5–10% of total daily dose every 1–2 weeks for outpatient; faster (10–25% per day) inpatient with monitoring

— Final 25% is hardest — slow to 2–5% reductions

— Cognitive behavioral therapy (CBT) for insomnia/anxiety — best non-pharm adjunct, improves taper success ~2-fold

— Gradual taper + psychoeducation letter from PCP: 25–40% discontinuation at 1 year

— Substituting another BZD chronically without taper plan

— Flumazenil-assisted "rapid detox" — not standard of care, seizure risk

— Abrupt switch to "non-addictive" anxiolytic without overlap

Step 3 management: The single most testable principle — physiologic dependence ≠ addiction, but both require structured taper. The order set in a CCS case: convert to diazepam equivalent, schedule taper, add CBT referral, address underlying anxiety with SSRI initiation (with overlap period), and arrange close follow-up.

Triage decision tree for the patient presenting with BZD withdrawal or use disorder:

Risk factors for complicated withdrawal:

First-line management principles:

Adjunctive strategies (evidence-based):

What does NOT work / can harm:

Pharmacotherapy — First-Line Regimens

— Diazepam 10–20 mg PO q1–2h until CIWA-B <20, then q4–6h PRN

— Lorazepam 2–4 mg PO/IV/IM q2h if hepatic dysfunction, elderly, or NPO (preferred for IM/IV reliability)

— Chlordiazepoxide 50–100 mg PO q2–4h — classic alcohol withdrawal agent, also used for combined alcohol+BZD withdrawal

— Monitor RR, sedation (RASS), and CIWA-B

— Step 1: convert current agent to diazepam (long t½ 20–80 h, self-tapers)

— Step 2: stabilize for 1 week at converted dose

— Step 3: reduce by 5–10% every 1–2 weeks

— Step 4: switch to clonazepam in last quarter if anxiety rebound prominent (smoother offset)

— Total taper duration: 8 weeks for short use, 6–12 months for chronic high-dose use

— Gabapentin 300–900 mg TID — reduces withdrawal severity, anxiety, helps insomnia; titrate per renal function

— Pregabalin 75–300 mg/day — similar profile, faster onset

— Carbamazepine 200–800 mg/day — reduces seizure risk in moderate withdrawal (limited use due to interactions)

— Trazodone 50–100 mg qhs for insomnia (avoid z-drugs — cross-tolerance and abuse potential)

— Propranolol 10–40 mg TID for autonomic symptoms; does NOT prevent seizures

— SSRIs (sertraline, escitalopram) or SNRIs (venlafaxine, duloxetine) — start during stable phase of taper, allow 4–6 weeks for effect

— Buspirone for GAD — non-addictive, takes 2–4 weeks

— Avoid restarting BZDs

Board pearl: Flumazenil in chronic users → precipitated withdrawal with status epilepticus, refractory to BZDs themselves (receptor blocked). Use only in pediatric iatrogenic oversedation or pure single-ingestion adult overdose with no chronic use history.

Inpatient acute withdrawal — symptom-triggered dosing (preferred over fixed schedule, reduces total BZD exposure):

Outpatient taper regimen:

Adjunctive medications (evidence variable, used selectively):

Treating underlying anxiety disorder (essential to prevent relapse):

Expanded Pharmacology and Special Scenarios

— Alprazolam 0.5–1 mg

— Lorazepam 1–2 mg

— Clonazepam 0.5 mg

— Oxazepam 30 mg

— Temazepam 20 mg

— Chlordiazepoxide 25 mg

— Midazolam 7.5 mg PO

— CYP3A4 metabolism: alprazolam, midazolam, triazolam — interactions with macrolides, azoles, protease inhibitors, grapefruit → toxicity risk

— Glucuronidation only (LOT): Lorazepam, Oxazepam, Temazepam — safe in liver disease, elderly

— Active metabolites: diazepam → nordiazepam (t½ 50–100 h), accumulates in renal/hepatic impairment

— BZD + opioid use disorder: treat both. Continue methadone or buprenorphine; do not stop OUD treatment to "remove sedation risk." Counsel on overdose, prescribe naloxone

— BZD + alcohol: combined CIWA monitoring, higher BZD doses often needed; thiamine, folate, Mg

— BZD + stimulants: treat sedative withdrawal first; stimulant "withdrawal" is dysphoria/sleep, not life-threatening

— Not detected on standard UDS

— Extreme potency — overdoses present like classic BZD but unresponsive to usual doses

— Treat as standard BZD withdrawal with diazepam loading

— 0.2 mg IV over 30 sec, repeat q1 min to max 3 mg

— Short t½ (1 h) → resedation common; rarely the right Step 3 answer

CCS pearl: In a hospitalized patient with chronic alprazolam dependence who is NPO for surgery, order scheduled lorazepam IV at diazepam-equivalent dose to prevent perioperative withdrawal. Forgetting this triggers seizure on POD 2 — a classic CCS pitfall scored heavily.

Equivalence table — memorize for CCS conversions (approximate diazepam 10 mg equivalents):

Pharmacokinetic principles affecting choice:

Polysubstance scenarios:

Designer/novel BZDs (etizolam, flualprazolam, clonazolam):

Reversal — flumazenil dosing if ever indicated:

Special Populations — Elderly and Renal/Hepatic Impairment

— Increased risk: falls, hip fractures, MVAs, delirium, cognitive impairment, dementia association

— Reduced clearance: diazepam t½ can exceed 200 h in elderly — accumulation over days

— Paradoxical disinhibition — agitation, aggression, especially with dementia

— EMPOWER trial / Choosing Wisely: patient-directed educational brochure → 27% discontinuation at 6 months

— Taper 25% q2 weeks initially, then 12.5% as approaching zero

— Substitute CBT-I for chronic insomnia, SSRI for anxiety, melatonin for sleep

— Avoid switching to z-drugs (zolpidem, eszopiclone) — same fall and cognitive risks

— Avoid: diazepam, chlordiazepoxide, alprazolam, midazolam (extensive CYP metabolism, active metabolites)

— Use lorazepam, oxazepam, temazepam (LOT) — glucuronidation only, no active metabolites

— Reduce dose by 50%, monitor for encephalopathy

— Lorazepam preferred; metabolites are inactive glucuronides excreted renally but cleared by dialysis

— Avoid clonazepam (active metabolite accumulates)

— Watch for propylene glycol toxicity with high-dose IV lorazepam (>10 mg/h) — anion gap metabolic acidosis, AKI

— Concurrent opioids → FDA black box, additive respiratory depression

— Concurrent gabapentinoids → also increased overdose risk; avoid triple therapy

Step 3 management: In a 78-year-old on temazepam 30 mg qhs for 10 years who fell and fractured her hip, the discharge plan must include a written taper schedule, CBT-I referral, fall-prevention assessment, and explicit communication to PCP — do not simply continue the BZD because "she's always been on it."

Elderly (≥65) — BZDs are on the AGS Beers Criteria "avoid" list:

Deprescribing in elderly (evidence-based, testable):

Hepatic impairment (cirrhosis, Child-Pugh B/C):

Renal impairment (CKD 4–5, ESRD):

Polypharmacy considerations:

Special Populations — Pregnancy, Pediatrics, Comorbid Psych

— BZDs cross placenta; older data suggested cleft lip/palate (small absolute risk increase, ~0.01%)

— Third-trimester use → neonatal "floppy infant syndrome" (hypotonia, hypothermia, poor feeding) and neonatal withdrawal (irritability, tremor, seizures) — 3–7 days postpartum

— Do NOT abruptly stop in pregnant patient with dependence — withdrawal seizures harm fetus more

— Approach: slow taper if feasible during pregnancy, coordinate with MFM and psychiatry, lowest effective dose, prefer lorazepam or clonazepam monotherapy

— Most BZDs enter milk in small amounts; short-acting lorazepam, oxazepam preferred

— Monitor infant for sedation, poor feeding; avoid diazepam (long-half-life metabolites accumulate in neonate)

— BZD ingestions in children — supportive care; flumazenil can be used in iatrogenic pediatric oversedation (procedural sedation) but contraindicated if mixed ingestion or chronic exposure

— Adolescent misuse rising — counterfeit "Xanax bars" with fentanyl; screen with CRAFFT

— PTSD — BZDs are contraindicated (worsen outcomes, impair extinction learning); first-line is sertraline, paroxetine, prazosin for nightmares, trauma-focused CBT/EMDR

— Panic disorder — SSRI + CBT first-line; BZD bridge ≤4 weeks acceptable while SSRI titrates

— Bipolar disorder — BZDs not maintenance; treat with mood stabilizer; BZD acute use risks misuse

— Borderline PD — BZDs may worsen disinhibition; DBT is preferred

— Active alcohol or opioid use disorder = relative contraindication to BZD prescription

— If BZD truly indicated, document risk/benefit, naloxone Rx, frequent visits, single prescriber/pharmacy contract

Board pearl: In PTSD with insomnia and anxiety, the wrong answer is "start clonazepam." The right answer combines SSRI + prazosin + trauma-focused therapy — BZDs are explicitly recommended against by VA/DoD guidelines.

Pregnancy:

Breastfeeding:

Pediatrics:

Psychiatric comorbidity (drives chronic use):

Co-occurring SUD:

Complications and Adverse Outcomes

— Withdrawal seizure — generalized tonic-clonic, usually within 24–72 h of last dose; status epilepticus possible, especially after flumazenil

— Withdrawal delirium — analogous to DTs, mortality 1–5% untreated; mimics alcohol withdrawal delirium

— Psychosis — paranoid, auditory hallucinations; resolves with BZD reload and gradual taper

— Hyperthermia, rhabdomyolysis in severe agitated withdrawal

— Pure BZD overdose rarely fatal in adults; mortality driven by co-ingestants (opioids, alcohol, TCAs)

— Aspiration pneumonia from depressed gag reflex

— Compartment syndrome / rhabdomyolysis from prolonged immobility

— Anoxic brain injury if respiratory arrest

— Cognitive impairment — memory, executive function; partial reversibility after discontinuation (months)

— Dementia risk — observational data suggest 1.5–2× increased dementia risk with long-term use; causality debated

— Falls and fractures — hazard ratio ~1.5; especially hip fractures in elderly

— MVAs — comparable to BAC 0.05–0.10%; counsel patients about driving

— Sleep architecture disruption — reduced slow-wave and REM sleep

— Sexual dysfunction, depression with chronic use

— Co-prescription with opioids → FDA boxed warning; quadruples overdose risk

— Initiation in hospital "for sleep" → 30% still on BZD 6 months later

— Polypharmacy with gabapentinoids, sedating antihistamines, antipsychotics

— BZD-involved overdose deaths in US ~12,000/year, ~85% with opioids

— All-cause mortality elevated in chronic users (HR ~1.5–2.0)

Key distinction: BZD withdrawal seizure is a single generalized event in a non-epileptic patient with recent cessation — load with diazepam/lorazepam, do not start chronic antiepileptic. If status epilepticus, IV lorazepam → fosphenytoin/levetiracetam → propofol/midazolam infusion per status protocol.

Acute complications:

Overdose complications:

Chronic use complications:

Iatrogenic harm patterns:

Mortality data:

When to Escalate Care — ICU, Consultation, Inpatient Triage

— Refractory withdrawal requiring continuous IV infusion (diazepam infusion, midazolam drip)

— Status epilepticus or recurrent seizures

— Hemodynamic instability (SBP >180 or <90 despite initial dosing)

— Delirium with safety risk

— Need for airway protection post-overdose

— Hyperthermia >39°C, rhabdomyolysis

— Severe polysubstance withdrawal (alcohol + BZD + opioid)

— CIWA-B 20–35 with adequate response to symptom-triggered dosing

— Seizure risk factors (prior withdrawal seizure, alprazolam >4 mg/day) but currently stable

— Pregnancy with BZD dependence

— Mild-moderate withdrawal on outpatient taper that decompensated

— Initiation of inpatient taper for failed outpatient attempts

— CIWA-B <20, stable vitals

— No seizure history, no polysubstance, reliable transportation

— Supportive sober contact at home

— Daily-to-weekly follow-up arranged

— Psychiatry/Addiction Medicine — within 24 h for all admitted BZD use disorder; essential for taper planning and motivational interviewing

— Social work — disposition, sober housing, peer recovery

— Pharmacy — equivalence conversions, taper schedule, drug interactions

— Neurology — if seizure atypical (focal, persistent post-ictal, status)

— OB/MFM — pregnant patients

— Toxicology / Poison Control (1-800-222-1222) — overdose, designer BZDs, unclear coingestants

— Community hospital → tertiary if ICU-level care or specialty addiction consultation unavailable

— Coordinate with intake to outpatient SUD program before discharge, not after

CCS pearl: Order psychiatry consult on Day 1, not Day 3. Late consultation is a graded omission. Pair with social work and a documented discharge SUD treatment plan including intake date — this combination is what the case rewards.

ICU admission criteria:

Stepdown / monitored bed:

General medical floor:

Outpatient management appropriate when:

Consultations to obtain:

Transfer considerations:

Key Differentials — Same-Category Causes

— Same GABA-A receptor mechanism, same CIWA scale family

— Timeline: tremor 6–12 h, seizures 12–48 h, DTs 48–96 h after last drink

— Distinguish: history, BAL, LFT pattern (AST:ALT >2), MCV elevated, GGT high

— Treat together if both present — symptom-triggered BZD covers both

— Phenobarbital, butalbital (Fioricet) — same GABA-A complex

— More dangerous than BZD withdrawal (mortality up to 30% untreated)

— Treat with phenobarbital taper

— Same receptor (BZD site of GABA-A), similar withdrawal but often milder

— Zolpidem abuse increasingly common; withdrawal seizures reported

— Cross-tolerance with BZDs — taper similarly

— Used as recreational drug; withdrawal more severe than BZD, rapid onset

— Treat with high-dose BZDs ± baclofen ± phenobarbital

— Metabolized to meprobamate (a BZD-like sedative)

— Withdrawal mimics BZD withdrawal — treat with BZD taper

— Less classically GABAergic but produces withdrawal: anxiety, insomnia, tremor, rarely seizures

— Taper, do not abruptly stop in chronic high-dose users

Key distinction: All sedative-hypnotic withdrawals respond to BZD/phenobarbital loading. The clue distinguishing BZD-specific withdrawal from alcohol withdrawal is history + UDS + LFT pattern — but treatment overlaps, so don't delay therapy waiting for the discriminator.

Alcohol withdrawal syndrome — overlapping presentation:

Barbiturate withdrawal:

Z-drug withdrawal (zolpidem, eszopiclone, zaleplon):

GHB / GBL withdrawal:

Carisoprodol (Soma) withdrawal:

Gabapentinoid withdrawal (gabapentin, pregabalin):

Kava and kratom co-use — increasingly seen; can produce sedation, withdrawal-like syndromes

Key Differentials — Other-Category Causes

— Often the reason BZDs were prescribed; recurrence mimics withdrawal

— Distinguish: autonomic findings less prominent, no tremor/hyperreflexia, normal vitals between episodes

— Resolves with SSRI + CBT, not BZD

— Tachycardia, tremor, anxiety, diaphoresis, weight loss

— TSH suppressed, free T4 elevated

— Treat with beta-blocker, methimazole, PTU

— Episodic HTN, headache, palpitations, diaphoresis

— Plasma metanephrines elevated

— Hyperreflexia, clonus (lower > upper), diarrhea, mydriasis, hyperthermia

— Recent SSRI/SNRI/MAOI/tramadol

— Treat: stop serotonergic agent, cyproheptadine

— Lead-pipe rigidity, hyperthermia, autonomic instability

— Antipsychotic exposure

— Treat: dantrolene, bromocriptine

— "Hot, dry, red, blind, mad" — dry skin, mydriasis, urinary retention, delirium

— TCAs, antihistamines, scopolamine

— Treat: physostigmine (selected cases)

— Tachycardia, HTN, mydriasis, agitation — but acute use, not withdrawal

— UDS positive

Board pearl: In a patient with autonomic hyperactivity and altered mentation, the Step 3 differential must include infection, ACS, PE, thyroid storm, and toxidromes before anchoring on BZD withdrawal. Always check glucose, troponin, lactate, and TSH as part of the parallel workup.

Primary anxiety/panic disorder:

Hyperthyroidism / thyroid storm:

Pheochromocytoma:

Serotonin syndrome:

Neuroleptic malignant syndrome:

Anticholinergic toxicity:

Sympathomimetic intoxication (cocaine, methamphetamine, MDMA):

Sepsis, meningitis, encephalitis — fever, altered mental status, tachycardia

Hypoglycemia — fingerstick on every altered patient

Acute coronary syndrome in older patients with chest tightness, diaphoresis — ECG and troponin

Pulmonary embolism — tachycardia, dyspnea, anxiety

Secondary Prevention, Discharge Medications, Long-Term Plan

— Continue diazepam or clonazepam taper at the dose patient is stable on, with written schedule and quantity-limited prescription (e.g., 1-week supply only)

— Avoid PRN BZD dispensing — schedule only

— SSRI or SNRI initiated/continued for underlying anxiety/depression

— Naloxone prescription if any opioid co-use or polypharmacy risk

— Gabapentin if used during withdrawal — taper or continue depending on indication

— Discontinue z-drugs and sedating antihistamines (diphenhydramine) — cross-tolerance, fall risk

— Written schedule given to patient AND PCP AND pharmacy

— Decrease 5–10% per 1–2 weeks; slower (2–5%) in final 25%

— Total duration 8 weeks (short use) to 12 months (chronic high-dose)

— "Holds" allowed at difficult steps — don't reverse, just pause

— CBT for anxiety, panic, insomnia — most evidence-based adjunct

— Motivational interviewing at each visit

— Mutual-help groups — SMART Recovery, AA/NA (less BZD-specific but addresses SUD)

— Mindfulness-based stress reduction

— Document agreement; check PDMP at every visit

— Random UDS quarterly

— Pill counts if concern

— Indicated for any patient with BZD + opioid, BZD use disorder, or prior overdose

— Educate household members

— Coordinate with insurer for behavioral health coverage

— Identify in-network addiction specialist before discharge

— Warm handoff to outpatient SUD clinic preferred over passive referral

Step 3 management: The discharge order set must include: taper Rx with limited quantity, SSRI, naloxone (if indicated), PCP follow-up within 1 week, addiction medicine intake within 2 weeks, CBT referral, and explicit "no early refills" documentation.

Discharge medication reconciliation — central Step 3 task:

Long-term taper structure:

Behavioral interventions:

Single prescriber / single pharmacy contract:

Naloxone co-prescribing:

Health systems considerations:

Follow-Up, Monitoring Parameters, Rehab and Counseling

— Week 1: in-person or telehealth visit, assess withdrawal symptoms, adjust taper

— Weeks 2–8: every 1–2 weeks during active taper

— Post-taper: monthly × 3 months, then quarterly × 1 year (relapse risk highest 0–3 months)

— More frequent visits = higher taper completion rates

— CIWA-B or subjective withdrawal scale

— PHQ-9, GAD-7 — track underlying psych symptoms

— Sleep quality (PSQI)

— Function (work, driving, relationships)

— UDS (random) — confirm adherence, screen co-use

— PDMP review — every visit

— Pill count if available

— LFTs if hepatic concern, baseline and during gabapentin/carbamazepine

— Renal function if on lorazepam IV or gabapentin

— ECG if antipsychotic adjunct (QTc)

— Outpatient counseling for most patients

— Intensive outpatient program (IOP) — 9–20 h/week, for moderate disorder

— Partial hospitalization (PHP) — 20–30 h/week

— Residential treatment — for severe, multiple relapses, polysubstance, unstable home

— Inpatient detox for medically complicated withdrawal

— Trigger identification, coping skills

— Sleep hygiene (foundational — replaces BZD for insomnia)

— Stimulus control, sleep restriction, relaxation training

— Family education and involvement

— Avoid driving during active taper if sedation present

— Document fitness for safety-sensitive occupations

— Written plan with warning signs, emergency contacts, naloxone access

— Identify high-risk situations

CCS pearl: Schedule the first follow-up within 7 days of discharge — this is the highest-yield order. Delayed follow-up (>2 weeks) correlates with relapse and is penalized in case scoring.

Follow-up cadence during outpatient taper:

At each visit, monitor:

Pharmacologic monitoring:

Rehab options — match to severity:

Counseling content:

Return-to-work / driving:

Relapse prevention plan:

Ethical, Legal, and Patient Safety Considerations

— Document discussion of: dependence risk, cognitive effects, fall/MVA risk, overdose with opioids/alcohol, withdrawal on cessation

— Re-consent annually

— Special caution in elderly — capacity may fluctuate

— PDMP query at every prescription (mandated in nearly all US states)

— Limit initial prescriptions: 2–4 weeks, lowest effective dose

— Avoid concurrent opioids when possible; if necessary, document rationale, prescribe naloxone, and use lowest doses

— Single prescriber / single pharmacy agreements for high-risk patients

— Impaired driver — varies by state; some mandate reporting to DMV (CA, OR, PA, NJ)

— Pregnant patients with SUD — some states require reporting to child protective services; know your state law, but fear of reporting should not deter treatment; federal CAPTA requires plan of safe care for substance-exposed newborns

— Suspected diversion by colleague — duty to report to licensing board / DEA

— Respect autonomy, document risk/benefit discussion

— Continue harm reduction: naloxone, lower dose, single prescriber

— Do not abandon — abrupt termination is unethical and dangerous; provide bridge prescription and referral

— Hospital discharge without taper plan → ED bounceback for withdrawal

— Specialist (psych) → PCP handoff: ensure written taper schedule, agreed dose, who refills

— Incarceration → coordinate with jail medical for taper continuation; abrupt cessation in custody has caused deaths and successful lawsuits

— Nursing home admission → reconcile chronic BZD, plan deprescribing

— Repeated early refill requests → reassess diagnosis, do not simply refuse; offer taper and SUD treatment

— "Doctor shopping" — refer to addiction medicine, not abandonment

Board pearl: Discharging a chronic BZD user from clinic without a taper plan or referral = patient abandonment, with legal and ethical liability. Always provide a bridge supply and documented referral.

Informed consent for chronic BZD prescribing:

Prescriber responsibilities:

Mandatory reporting:

Patients with capacity who refuse taper:

Transition-of-care risks (high-yield Step 3):

Boundary issues:

High-Yield Associations and Rapid-Fire Clinical Facts

— Alprazolam 0.5–1 mg, Lorazepam 1–2 mg, Clonazepam 0.5 mg, Oxazepam 30 mg, Temazepam 20 mg

— Short (<12 h): triazolam, midazolam, alprazolam IR, oxazepam

— Intermediate (12–40 h): lorazepam, temazepam, clonazepam

— Long (>40 h): diazepam, chlordiazepoxide, flurazepam

— Diazepam → nordiazepam, oxazepam, temazepam

— Chlordiazepoxide → desmethylchlordiazepoxide, demoxepam

Step 3 management: When in doubt, the right answer involves PDMP check, gradual taper, SSRI initiation, CBT referral, and naloxone co-prescription — almost never "continue current dose" or "stop abruptly."

Mechanism: BZDs bind α-subunit of GABA-A receptor → ↑ frequency of Cl⁻ channel opening → hyperpolarization. Barbiturates ↑ duration. Alcohol acts on same complex.

Z-drugs (zolpidem, eszopiclone, zaleplon) bind α1 selectively → sedation without much anxiolysis; same addiction/withdrawal risk.

Flumazenil: competitive GABA-A antagonist at BZD site; t½ ~1 h; precipitates seizures in chronic users.

Beers Criteria: avoid all BZDs in adults ≥65 except for seizure, REM behavior disorder, severe GAD, end-of-life care, alcohol withdrawal.

FDA boxed warning (2020): BZDs — risk of abuse, misuse, addiction, physical dependence, withdrawal reactions.

DEA Schedule IV — all BZDs.

Equivalence quick recall (to 10 mg diazepam):

Half-life categories:

Active metabolites:

PTSD: BZDs are contraindicated (VA/DoD guidelines).

CBT-I is first-line for chronic insomnia, not BZDs.

Pregnancy: floppy infant syndrome, neonatal withdrawal.

UDS misses: alprazolam, lorazepam, clonazepam (immunoassay).

Designer BZDs (etizolam, flualprazolam) increasingly in counterfeit pills, often with fentanyl.

Opioid + BZD co-Rx: 4× overdose mortality.

Withdrawal seizures typically generalized, single, within 24–72 h of last short-acting BZD or 3–8 days for long-acting.

Buspirone, SSRIs, SNRIs, hydroxyzine = non-addictive anxiety alternatives.

EMPOWER trial — patient-directed deprescribing brochure works.

Board Question Stem Patterns

— 38-year-old woman on alprazolam 2 mg QID × 5 years requests early refills, PDMP shows 3 prescribers. → Answer: discuss findings empathetically, convert to diazepam, initiate gradual taper, refer for CBT, start sertraline for underlying GAD. Wrong: abrupt stop, simple refusal, increasing dose.

— 55-year-old hospitalized for pneumonia, on chronic clonazepam 2 mg BID, NPO, develops tremor, HR 120, BP 165/95, anxiety at 36 h. → Answer: scheduled lorazepam IV (clonazepam equivalent), CIWA-B monitoring, do not wait for seizure. Wrong: PRN-only, haloperidol monotherapy, flumazenil.

— 22-year-old found unresponsive after "Xanax bars" from a friend, RR 8, pinpoint pupils. → Answer: naloxone (suspect fentanyl contamination), supportive airway, NOT flumazenil. Polysubstance assumption.

— 45-year-old runs out of alprazolam 3 days ago, witnessed generalized seizure. → Answer: IV lorazepam load, admit, initiate diazepam taper, do NOT start chronic AED.

— 78-year-old on temazepam 15 mg qhs × 12 years, hip fracture from fall. → Answer: initiate gradual taper, CBT-I, melatonin, fall prevention; do NOT continue indefinitely.

— 28-year-old G2P1 at 10 weeks on clonazepam 1 mg BID for panic disorder. → Answer: continue lowest effective dose, MFM/psychiatry co-management, do NOT abruptly stop; switch to SSRI (sertraline) with overlap.

— Veteran with PTSD on alprazolam reports worsening nightmares. → Answer: taper BZD, start sertraline + prazosin + trauma-focused therapy.

— Chronic pain patient on oxycodone, request "Xanax for anxiety." → Answer: non-BZD anxiolytic (SSRI, buspirone), CBT; if BZD already on board, taper one, naloxone Rx.

— Young adult with sedation, UDS negative for BZD but clinical picture classic. → Answer: send LC-MS for designer BZDs (etizolam, flualprazolam), treat clinically.

Board pearl: Step 3 BZD questions reward gradual taper + treat underlying disorder + harm reduction + close follow-up. Watch for distractor answers offering abrupt cessation, flumazenil, or simple prescription refusal.

Stem 1 — Outpatient escalating use:

Stem 2 — Inpatient withdrawal:

Stem 3 — Overdose:

Stem 4 — Withdrawal seizure:

Stem 5 — Elderly fall:

Stem 6 — Pregnancy:

Stem 7 — PTSD prescribed BZD:

Stem 8 — Co-prescribed opioid:

Stem 9 — Designer BZD:

One-Line Recap

Benzodiazepine use disorder and withdrawal demand the same clinical reflex: never stop a chronic benzodiazepine abruptly — convert to a long-acting agent, taper gradually over weeks to months, treat the underlying psychiatric driver with SSRIs and CBT, and protect against overdose with PDMP review and naloxone.

Step 3 management: Convert → taper → treat underlying disorder → coordinate care → prevent overdose. This sequence answers nearly every BZD vignette on the exam.

Withdrawal physiology mirrors alcohol — GABA-A downregulation produces autonomic hyperactivity, seizures, and delirium; severity tracks with potency (alprazolam > clonazepam), short half-life, high dose, and abrupt cessation; CIWA-B guides symptom-triggered diazepam or lorazepam dosing.

Taper architecture — convert current BZD to diazepam-equivalent dose, stabilize 1 week, then reduce 5–10% every 1–2 weeks (slower in final 25%); outpatient appropriate for mild withdrawal with reliable support, inpatient/ICU for seizures, delirium, polysubstance, pregnancy, or hemodynamic instability.

Treat the why — most chronic BZD users have underlying GAD, panic, PTSD, or insomnia; replace with SSRI/SNRI + CBT/CBT-I, never with z-drugs (same risk profile); BZDs are contraindicated in PTSD and on Beers list for elderly.

Safety net at discharge — PDMP query at every visit, single prescriber/pharmacy, naloxone co-prescription if any opioid co-use, limited-quantity scripts, follow-up within 1 week, addiction medicine intake within 2 weeks, and explicit documentation of taper plan shared with PCP — flumazenil is almost always the wrong Step 3 answer in chronic users because it precipitates refractory seizures.